Crohn's Disease (CD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Crohn’s Disease (CD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, “Crohn’s Disease (CD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global Crohn’s Disease Therapeutics market. The report identifies the key trends shaping and driving the global Crohn’s Disease Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Crohn’s Disease Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

GlobalData has estimated that the global Crohn’s disease (CD) therapeutics market was worth $3.6 billion in 2010 which grew at a compound annual growth rate (CAGR) of 25.2%, from $1.2 billion in 2005. This high growth rate during the period 2005-2010 was primarily attributed to the launch of the biologics such as Humira (adalimumab), Cimzia (certolizumab pegol) and Tysabri (natalizumab) and the increased uptake of the biologics Remicade (infliximab) and Entocort EC (budesonide). The CD therapeutics market is forecast to show moderate growth at a CAGR of 2.6% for the next eight years, to reach $4.4 billion by 2018. This reduced growth will come as a result of the patent expiries of Remicade and Entocort EC and the subsequent launch of biosimilars in the forecast period. The CD therapeutics pipeline is strong, with first-in-class molecules in the late stage of development, which when launched are expected to off-set the generic incursion and drive the market.

Scope

The report provides information on the key drivers and challenges for the CD therapeutics market. Its scope includes -
- Annualized information for the CD therapeutics market in the seven key markets (the US, France, Germany, Italy, Spain, the UK and Japan) with revenue data from 2005–2010 and forecasts to 2018.
- Pipeline analysis data which provides information on different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as interleukin inhibitors and enzyme inhibitors, stem cell therapy, integrin antagonists, tumor necrosis inhibitors and immunomodulators.
- Analysis of current and future competition in the global CD therapeutics market. Key market companies covered are: GlaxoSmithKline plc, Johnson & Johnson, Osiris Therapeutics, Inc., and Takeda Pharmaceutical Company Limited..
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and implications for the CD therapeutics market.
- Analysis of key recent licensing and partnership agreements in the CD therapeutics market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and through identification of companies with the strongest pipelines.
- Develop business strategies through understanding of the trends which shape and drive the global CD therapeutics market.
- Drive revenues by understanding key trends, innovative products and technologies, market segments and companies likely to impact the global CD therapeutics market in the future.
- Formulate effective sales and marketing strategies through understanding of the competitive landscape and analysis of the performance of various competitors.
- Identify emerging companies with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying market categories and segments that present the best opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global CD therapeutics market landscape? Identify, understand and capitalize.

Keywords

Pharma, Pharmaceuticals, Healthcare, Deal Value, Deal Volume, Private Equity, Venture Capital, Partnership, Licensing, Agreements, North America, Europe, Asia-Pacific, Rest of the World (ROW), Merger, M&A, Acquisition, Equity Offering, Debt Offering, Capital raising, Asset Purchase, Private Placement, Secondary offering, IPO, Initial Public Offer, cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, women's health, Upfront Payment, Milestone Payment, Phases, Clinical Trials SHOW LESS READ MORE >

1
1

1.1 List of Tables
1.2 List of Figures
2 Crohn’s Disease(CD) Therapeutics - Introduction
2.1 Overview
2.2 Types of CD
2.3 Perianal Complications
2.3.1 Classification of Perianal Complications
2.4 CD Diagnosis and Classification based on Severity and Location
2.5 Epidemiology
2.6 Etiology
2.7 Signs and Symptoms
2.8 Extraintestinal Manifestations of CD
2.9 Diagnosis of CD
2.10 Pathophysiology
2.11 Treatment and Management Pattern
2.11.1 Medical or Pharmacological Management of CD
2.11.2 Surgical Management of CD
2.12 GlobalData Report Guidance
3 Crohn’s Disease (CD) Therapeutics - Market Characterization
3.1 CD Therapeutics Market Size (2005 - 2010) - Global
3.2 CD Therapeutics Market Forecast (2010 - 2018) - Global
3.3 CD Therapeutics Market Size (2005 - 2010) - The US
3.4 CD Therapeutics Market Forecast (2010 - 2018) - The US
3.5 CD Therapeutics Market Size (2005 - 2010) - France
3.6 CD Therapeutics Market Forecast (2010 - 2018) - France
3.7 CD Therapeutics Market Size (2005 - 2010) - Germany
3.8 CD Therapeutics Market Forecast (2010 - 2018) - Germany
3.9 CD Therapeutics Market Size (2005 - 2010) - Italy
3.10 CD Therapeutics Market Forecast (2010 - 2018) - Italy
3.11 CD Therapeutics Market Size (2005 - 2010) - Spain
3.12 CD Therapeutics Market Forecast (2010 - 2018) - Spain
3.13 CD Therapeutics Market Size (2005 - 2010) - The UK
3.14 CD Therapeutics Market Forecast (2010 - 2018) - The UK
3.15 CD Therapeutics Market Size (2005 - 2010) - Japan
3.16 CD Therapeutics Market Forecast (2010 - 2018) - Japan
3.17 Drivers and Barriers for the CD Therapeutics Market
3.17.1 Drivers for the CD Therapeutics Market
3.17.2 Barriers for the CD Therapeutics Market
3.18 Key Events Impacting the Future Market
3.19 Opportunity and Unmet Need
3.20 Key Takeaway
4 Crohn`s Disease (CD) Therapeutics - Competitive Assessment
4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Product Profile for the Major Marketed Products in the CD Therapeutics Market
4.3.1 Entocort EC (budesonide)
4.3.2 Humira (adalimumab)
4.3.3 Tysabri (natalizumab)
4.3.4 Remicade (infliximab)
4.3.5 Cimzia (cetrolizumab pegol)
4.4 Key Takeaway
5 Crohn`s Disease (CD) Therapeutics - Pipeline Assessment
5.1 Overview
5.2 Strategic Pipeline Assessment
5.3 CD Therapeutics Pipeline Analysis - Pipeline by Phases of Development
5.3.1 CD Therapeutics - Phase III Pipeline
5.3.2 CD Therapeutics - Phase II/III Pipeline
5.3.3 CD Therapeutics - Phase II Pipeline
5.3.4 CD Therapeutics - Phase I/II Pipeline
5.3.5 CD Therapeutics - Phase I Pipeline
5.3.6 CD Therapeutics - Preclinical Pipeline
5.3.7 CD Therapeutics - Discovery Pipeline
5.4 CD Therapeutics- Clinical Pipeline by Mechanism of Action
5.5 CD Therapeutics-Technology Trends Analytical Framework
5.6 CD Therapeutics - Promising Drugs with Novel mechanisms of action under Clinical Development
5.7 Molecule Profile for Late-stage Drugs under Clinical Development
5.7.1 Traficet-EN (CCX282)
5.7.2 Vedolizumab (MLN0002)
5.7.3 Prochymal
5.7.4 Stelara
5.8 Key Takeaway
6 Crohn’s Disease (CD) Therapeutics - Clinical Trials Mapping
6.1 Clinical Trials by Country (US, EU5 and Japan)
6.2 Clinical Trials by Phase
6.3 Clinical Trials by Trial Status
6.4 Overall Sponsors
6.5 Prominent Sponsor
6.6 Top Companies Participating in Therapeutics Clinical Trials, 2011
7 Crohn’s Disease (CD) Therapeutics - Strategic Assessment
7.1 CD Therapeutics Market - Implications for Future Market Competition
8 Crohn’s Disease (CD) Therapeutics - Future Players
8.1 Introduction
8.2 Company Profile
8.2.1 GlaxoSmithKline
8.2.2 Johnson & Johnson
8.2.3 Osiris Therapeutics, Inc.
8.2.4 Takeda Pharmaceutical Company Limited
9 Crohn`s Disease (CD) Therapeutics - Licensing and Partnership Deals
10 Crohn`s Disease (CD) Therapeutics - Appendix
10.1 Definitions
10.2 Acronyms
10.3 Research Methodology
10.3.1 Coverage
10.3.2 Secondary Research
10.3.3 Forecasting
10.3.4 Primary Research
10.3.5 Expert Panel Validation
10.4 Contact Us
10.5 Disclaimer
10.6 Bibliography

1.1 List of Tables
Table 1: Definitions of CD Activity
Table 2: Estimated Prevalence of CD in the Seven Major Key Markets
Table 3: Extraintestinal Manifestations of CD
Table 4: CD Therapeutics Market, Global, Revenue ($bn), 2005 - 2010
Table 5: CD Therapeutics Market, Global, Forecast ($bn), 2010 - 2018
Table 6: CD Therapeutics Market, The US, Revenue ($bn), 2005 - 2010
Table 7: CD Therapeutics Market, The US, Forecast ($bn), 2010 - 2018
Table 8: CD Therapeutics Market, France, Revenue ($m), 2005 - 2010
Table 9: CD Therapeutics Market, France, Forecast ($m), 2010 - 2018
Table 10: CD Therapeutics Market, Germany, Revenue ($m), 2005 - 2010
Table 11: CD Therapeutics Market, Germany, Forecast ($m), 2010 - 2018
Table 12: CD Therapeutics Market, Italy, Revenue ($m), 2005 - 2010
Table 13: CD Therapeutics Market, Italy, Forecast ($m), 2010 - 2018
Table 14: CD Therapeutics Market, Spain, Revenue ($m), 2005 - 2010
Table 15: CD Therapeutics Market, Spain, Forecast ($m), 2010 - 2018
Table 16: CD Therapeutics Market, The UK, Revenue ($m), 2005 - 2010
Table 17: CD Therapeutics Market, The UK, Forecast ($m), 2010 - 2018
Table 18: CD Therapeutics Market, Japan, Revenue ($m), 2005 - 2010
Table 19: CD Therapeutics Market, Japan, Forecast ($m), 2010 - 2018
Table 20: CD Therapeutics - Phase III Pipeline, 2011
Table 21: CD Therapeutics - Phase II/III Pipeline, 2011
Table 22: CD Therapeutics - Phase II Pipeline, 2011
Table 23: CD Therapeutics - Phase I/II Pipeline, 2011
Table 24: CD Therapeutics - Phase I Pipeline, 2011
Table 25: CD Therapeutics - Preclinical Pipeline, 2011
Table 26: CD Therapeutics - Discovery Pipeline, 2011
Table 27: CD Therapeutics - Mechanism of Action That Constitute Others in the Pie Chart in Figure 29
Table 28: Crohn’s Disease Therapeutics - Most Promising Drugs Under Clinical Development
Table 29: CD Therapeutics - Clinical Trials by Country, 2011
Table 30: CD Therapeutics - Clinical Trials by Phase, 2011
Table 31: CD Therapeutics - Clinical Trials by Status, 2011
Table 32: CD Therapeutics - Overall Sponsors, 2011
Table 33: CD Therapeutics - Prominent Sponsors, 2011
Table 34: CD Therapeutics - Top Companies Participating in Therapeutics Clinical Trials, 2011
Table 35: GlaxoSmithKline (GSK) Autoimmune and Gastrointestinal Disease Pipeline Products, June 2011
Table 36: Johnson & Johnson (J&J) Autoimmune and Gastrointestinal Disease Pipeline Products, 2011
Table 37: Osiris Inc, Autoimmune and Gastrointestinal Disease Pipeline Products, June 2011
Table 38: Takeda Pharmaceutical Company Limited Autoimmune and Gastrointestinal Disease Pipeline Products, June 2011
Table 39: Licensing and Partnership Deals

1.2 List of Figures
Figure 1: Pathophysiology of CD
Figure 2: ICD Treatment Algorithm
Figure 3: Perianal Complications Treatment Algorithm
Figure 4: CD Therapeutics Market, Global, Revenue ($bn), 2005 - 2010
Figure 5: CD Therapeutics, Market Share ($m, %), 2010
Figure 6: CD Therapeutics Market, Global, Forecast ($bn), 2010 - 2018
Figure 7: CD Therapeutics, Market Share ($m, %), 2018
Figure 8: CD Therapeutics Market, The US, Revenue ($bn), 2005 - 2010
Figure 9: CD Therapeutics Market, The US, Forecast ($bn), 2010 - 2018
Figure 10: CD Therapeutics Market, France, Revenue ($m), 2005 - 2010
Figure 11: CD Therapeutics Market, France, Forecast ($m), 2010 - 2018
Figure 12: CD Therapeutics Market, Germany , Revenue ($m), 2005 - 2010
Figure 13: CD Therapeutics Market, Germany , Forecast ($m), 2010 - 2018
Figure 14: CD Therapeutics Market, Italy, Revenue ($m), 2005 - 2010
Figure 15: CD Therapeutics Market, Italy, Forecast ($m), 2010 - 2018
Figure 16: CD Therapeutics Market, Spain, Revenue ($m), 2005 - 2010
Figure 17: CD Therapeutics Market, Spain, Forecast ($m), 2010 - 2018
Figure 18: CD Therapeutics Market, The UK, Revenue ($m), 2005 - 2010
Figure 19: CD Therapeutics Market, The UK, Forecast ($m), 2010 - 2018
Figure 20: CD Therapeutics Market, Japan, Revenue ($m), 2005 - 2010
Figure 21: CD Therapeutics Market, Japan, Forecast ($m), 2010 - 2018
Figure 22: CD Therapeutics, Key Events Impacting Future Market
Figure 23: Opportunity and Unmet Need in the CD Therapeutics Market,2010
Figure 24: Strategic Competitor Assessment of the Major Marketed Products in CD, 2010
Figure 25: CD Therapeutics Pipeline by Phase of Clinical Development, 2011
Figure 26: CD Therapeutics-Clinical Pipeline by Mechanism of Action
Figure 27: Technology Trends Analytical Framework of The CD Therapeutics Pipeline, 2011
Figure 28: Technology Trends Analytical Framework of The CD Therapeutics Pipeline - Description, 2011
Figure 29: CD Therapeutics - Clinical Trials by Country, 2011
Figure 30: CD Therapeutics - Clinical Trials by Phase, 2011
Figure 31: CD Therapeutics - Clinical Trials by Status, 2011
Figure 32: CD Therapeutics - Overall Sponsors, 2011
Figure 33: CD Therapeutics - Prominent Sponsors, 2011
Figure 34: CD Therapeutics - Top Companies Participating in Therapeutics Clinical Trials, 2011
Figure 35: Implications for Future Market Competition in the CD Therapeutics Market, 2010
Figure 36: CD Therapeutics Market, Clinical Pipeline by Company, June 2011
Figure 37: GlobalData Market Forecasting Model

GlobalData, the industry analysis specialist, has released its new report, “Crohn’s Disease (CD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global Crohn’s Disease Therapeutics market. The report identifies the key trends shaping and driving the global Crohn’s Disease Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Crohn’s Disease Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

The CD Therapeutics Market is Forecast to Show Increased Growth up to 2018

GlobalData has estimated that the global Crohn’s Disease (CD) therapeutics market was worth $3.6 billion in 2010, which grew at a compound annual growth rate (CAGR) of 25.2% from $1.2 billion in 2005. This high growth rate, during the period 2005-2010, was primarily attributed to the launch of biologics such as Humira (adalimumab), Cimzia (certolizumab pegol) and Tysabri (natalizumab) and the increased uptake of the biologics Remicade (Infliximab) and Entocort EC (budesonide). The CD therapeutics market is forecast to show moderate growth, at a CAGR of 2.6% for the next eight years, to reach $4.4 billion by 2018. This reduced growth will come as a result of the patent expiries of Remicade and Entocort EC and the subsequent launch of biosimilars in the forecast period. The CD therapeutics pipeline is strong, with first-in-class molecules in the late stage of development, which when launched are expected to off-set the generic incursion and drive the market.

CD Therapeutics Market, Global, Revenue and Forecast ($bn), 2005-2018

Source:GlobalData, Economou and Pappas et al., New Global Map of Crohn’s Disease: Genetic, Environmental, and Socioeconomic Correlations, Inflamm Bowel Dis, Page No. 1-12, Edward v. Loftus, jr., Clinical Epidemiology of Inflammatory Bowel Disease Incidence, Prevalence, and Environmental Influences, Gastroenterology 2004;126:1504 - 1517; GlobalData Epidemiology-based Market Forecasting Model; Primary Research Interviews; KOL Interviews

GlaxoSmithKline
Johnson & Johnson
Osiris Therapeutics, Inc.
Takeda Pharmaceutical Company Limited